A full course of BV treatment
in one oral dose1

Solosec (secnidazole) is the first and only bacterial vaginosis (BV) treatment designed to deliver a complete course of therapy in just one oral dose1,2

SCROLL

Treatment completion can be challenging to your BV patients for many reasons.2-4

Solosec offers them an easy one-dose oral treatment option that may potentially improve adherence.5

Even though BV is common, treatment can be challenging. Find out why.2-4

Explore BV Challenges

Solosec was proven to be effective and generally well tolerated in pivotal trials.1,6,7

View Efficacy Trials

Solosec provides effective treatment with less exposure and medication.1,5

See Pharmacokinetic Properties

Solosec was designed to be easy to take—a full course of treatment in one oral dose.1,8

Dosing Explained

STAY INFORMED

Get more information about how single-dose Solosec can help your patients.1

Learn More

REFERENCES:

  1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2017.
  2. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv Ther. 2000;17(3):159-166.
  3. Centers for Disease Control and Prevention. Sexually transmitted diseases: treatment guidelines, 2015. Morbid Mortal Wkly Rep (MMWR). 2015;64(3):1-140.
  4. Data on File, Patient Research. Symbiomix, a Lupin Company. 2013.
  5. Nyirjesy P, Schwebke JR. Future Microbiol. 2018; doi: 10.2217/fmb-2017-0270.
  6. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1- 678.e9. doi: 10.1016/j.ajog.2017.08.017.
  7. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017 Aug;130(2):379-386.
  8. Data on File, Physician Research. Advantage Healthcare, Inc. Prepared December 23, 2014.